Evaxion A/S (NASDAQ:EVAX) Share Price Crosses Below 200-Day Moving Average – Time to Sell?

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.55 and traded as low as $2.95. Evaxion A/S shares last traded at $3.08, with a volume of 219,538 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 6th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Evaxion A/S currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Evaxion A/S Stock Performance

The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69. The stock has a market cap of $28.06 million, a P/E ratio of -2.57 and a beta of 0.50. The stock has a fifty day simple moving average of $3.19 and a 200-day simple moving average of $3.53.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Rathbones Group PLC acquired a new stake in Evaxion A/S in the first quarter worth $170,000. Renaissance Technologies LLC acquired a new position in shares of Evaxion A/S in the 1st quarter valued at $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Evaxion A/S in the 1st quarter valued at $112,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to develop novel immunotherapies and vaccines. Its proprietary AI-Immunology platform is designed to analyze biological data, identify disease-specific targets and support the development of treatments tailored to individual patients or pathogens.

The company’s research and development activities focus primarily on personalized cancer vaccines and vaccines for infectious diseases. Evaxion’s pipeline has included programs intended to stimulate the immune system to recognize and attack cancer cells, as well as vaccine candidates targeting bacterial and viral infections.

Evaxion is headquartered in Copenhagen, Denmark, and conducts its work through an international biotechnology and research network.